Wellgistics Health, Inc.'s (NASDAQ:WGRX) Lock-Up Period Set To Expire on August 20th

Key Points

• The lock-up period for Wellgistics Health, Inc. (NASDAQ:WGRX) is set to expire on August 20th, allowing major shareholders to sell their shares.
• Wellgistics Health's stock opened at $0.71 and has experienced a fifty-two week range between $0.70 and $7.04.
• Wall Street Zen downgraded Wellgistics Health from a "hold" to a "sell" rating on July 26th.

Wellgistics Health's (NASDAQ:WGRX - Get Free Report) lock-up period is set to expire on Wednesday, August 20th. Wellgistics Health had issued 888,889 shares in its IPO on February 21st. The total size of the offering was $4,000,001 based on an initial share price of $4.50. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered Wellgistics Health from a "hold" rating to a "sell" rating in a research report on Saturday, July 26th.

Wellgistics Health Price Performance

NASDAQ:WGRX opened at $0.71 on Wednesday. The company has a debt-to-equity ratio of 1.43, a current ratio of 0.36 and a quick ratio of 0.15. Wellgistics Health has a fifty-two week low of $0.70 and a fifty-two week high of $7.04. The firm's 50 day moving average price is $0.96.

About Wellgistics Health

Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.